| Oct 25 |
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares
|
| Oct 25 |
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
|
| Oct 24 |
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
|
| Oct 9 |
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
|
| Sep 27 |
Fortress Biotech files to sell 6.19M shares of common stock for holders
|
| Sep 26 |
Fortress Biotech to Participate in October 2024 Investor Conferences
|
| Sep 20 |
Why Fortress Biotech (FBIO) Stock Is Getting Hammered
|
| Sep 20 |
Fortress Biotech to sell 3.9M shares at $1.65 in registered direct offering
|
| Sep 20 |
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
|
| Sep 16 |
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
|
